Ultragenyx Pharmaceutical stock
RARENASDAQUltragenyx Pharmaceutical Inc., HealthcareISIN US90400D1081
38Score 38 out of 100, Weak
Price and trend
54 / 100
Price history
−51% in one yearThe chart shows daily closes over 13 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 28% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 54).
The price is 55% below its 52-week high. Largest decline in 13 years: 93% (December 2020 to September 2026).
Chart figures for advanced users
- SMA 50$15.27
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$22.57
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)54
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$12.88
- The lowest closing price of the last twelve months.
- Resistance$36.54
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Ultragenyx Pharmaceutical Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.66B, is number 145 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $673M (up 20.1% year on year) and a loss of $575M.
- For fiscal 2026, analysts expect on average revenue of $751.87M (up 11.7%) and adjusted earnings per share of −$4.52.
Show more
- MEQIRI Score 38 out of 100 (Weak): rank 567 of 702 in Healthcare, median 53.
- Our model puts fair value at $22.12, with the price 26% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 62% since 2020.Capital allocation 18
- Loss-makingLoss of $524M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 82% a year over the last 12 months.Stability 26
Its standout strength is valuation, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
- price far below its 52-week high
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $14.75 and expensive above $44.25 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 12.1%. At 13.1% the fair value would be $19.64, at 11.1% it would be $25.27.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 15.8% on the twelve months before. Revenue turned from negative at the start of the period to positive ($673M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 84%, operating −79%, net −85%. Last 12 months: net −72%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 11 Feb 2027in 90 days
- Last reported
- 3 Nov 2026EPS reported −$1.16 (expected −$1.10)below expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 102.5% since 15 Oct 2026.
- Earnings per share
- −$4.52+1.4%
- Revenue
- $751.87M−0.6%
- Earnings per share
- $0.02+102.5%
- Revenue
- $994.3M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −0.4%2026 revenue guidance and combined R&D and SG&A expense guidance reaffirmed after record quarterly revenue.
“The commercial team delivered the highest quarterly revenue in the history of the company, which supports our reaffirmed full-year revenue guidance.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $799,222 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Horn HowardSale
15 Oct 2026, Chief Financial Officer
- Shares
- 7,066
- Price
- $15.27
- Value
- $107,898
- Huizenga Theodore AlanSale
15 Sept 2026, SVP, Chief Accounting Officer
- Shares
- 1,283
- Price
- $13.57
- Value
- $17,410
- Huizenga Theodore AlanSale
3 Sept 2026, SVP, Chief Accounting Officer
- Shares
- 161
- Price
- $13.99
- Value
- $2,252
Show 7 more
- Parschauer Karah HerdmanSale
3 Aug 2026, EVP and Chief Legal Officer
- Shares
- 1,900
- Price
- $24.92
- Value
- $47,348
- Horn HowardSale
3 Aug 2026, Chief Financial Officer
- Shares
- 4,696
- Price
- $24.92
- Value
- $117,024
- Horn HowardSale
1 Jul 2026, Chief Financial Officer
- Shares
- 4,698
- Price
- $33.13
- Value
- $155,645
- Sanders Corazon (Corsee) D.Sale
15 Jun 2026, Board
- Shares
- 2,000
- Price
- $25.05
- Value
- $50,100
- Parschauer Karah HerdmanSale
15 Jun 2026, EVP and Chief Legal Officer
- Shares
- 1,899
- Price
- $24.62
- Value
- $46,753
- Horn HowardSale
1 Jun 2026, Chief Financial Officer
- Shares
- 4,653
- Price
- $23.77
- Value
- $110,602
- Suliman ShehnaazSale
18 May 2026, Board
- Shares
- 5,740
- Price
- $25.12
- Value
- $144,189
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Ultragenyx Pharmaceutical
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 38
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Taysha Gene TherapiesTSHA $1.71B35
- Nurix TherapeuticsNRIX $1.7B68
- MesoblastMESO $1.7B37
- PrecigenPGEN $1.67B54
- NanobiotixNANO.PA $1.64B38
- SELLAS Life Sciences GroupSLS $1.62B35
- Generate BiomedicinesGENB $1.61B36
- Immunocore HoldingsIMCR $1.57B45
ETFs that hold Ultragenyx Pharmaceutical
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 1.20% | 0.50% | €127.64M |
| iShares Ageing Population UCITS ETF2B77 | 0.12% | 0.40% | €813.42M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.10% | 0.35% | €1.25B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.05% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.05% | 0.30% | €2.22B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.04% | 0.30% | €185.82M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.54B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.5B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2015)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.